Another Attempt To Expand Nexavar Label Ends In Disappointment
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer/Amgen’s Nexavar fails to improve progression-free survival in a Phase III HER2-negative breast cancer study. Approved indications are not affected, the companies note.